CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）

Status Recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML

Clinical Trial Description

The relapsed/refractory AML patients will receive FC (F,Fludarabine，C，Cyclophosphamide) chemotherapy followed by infusion of allogenic or autologous CD123-Targeted CAR-T cells.No graft-versus-host disease (GVHD) prevention will be conducted before or after infusion. Dose-limiting toxicity,incidence of adverse events and disease response will be detected post-infusion. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03556982
Study type	Interventional
Source	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Contact	HUISHENG AI
Phone	8610-66947126
Email	HUISHNGAI@163.COM
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	March 1, 2018
Completion date	March 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05319587` - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)	Phase 1/Phase 2
Active, not recruiting	`NCT04090736` - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy	Phase 3
Completed	`NCT01617226` - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS	Phase 2
Terminated	`NCT00957580` - Trial of Pimasertib in Hematological Malignancies	Phase 2
Terminated	`NCT00916045` - Pilot Study of Unrelated Cord Blood Transplantation	Phase 2
Completed	`NCT00640796` - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors	Phase 1
Completed	`NCT00458250` - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H	Phase 1
Active, not recruiting	`NCT05424380` - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS	Phase 1
Completed	`NCT01690624` - BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse	Phase 1
Recruiting	`NCT05471700` - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients	Phase 1/Phase 2
Not yet recruiting	`NCT05016063` - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia	Early Phase 1
Not yet recruiting	`NCT04450784` - ObServatory Children Acute RElated Therapy Leukemia
Recruiting	`NCT04265963` - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Terminated	`NCT04968860` - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting	`NCT03793517` - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT	Phase 2/Phase 3
Terminated	`NCT02841540` - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes	Phase 1
Recruiting	`NCT05453903` - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies	Phase 1
Completed	`NCT03720366` - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients	Phase 1
Withdrawn	`NCT04230564` - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated	`NCT03761069` - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias	Phase 1